Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not professional

advice and should not be used in lieu of obtaining advice from a qualified health care provider.

And now on to the show.

Welcome to Helix Talk episode 76. I'm your co-host, Dr. King. I'm Dr. Patel. And I'm Dr. Schumann.

And I'm excited today to bring in a guest lecture with us.

Dr. Shannon Furbish.

Dr. Furbush is one of our PGI2 Psychiatric Pharmacy residents at Captain James A. Level Federal

Healthcare Center.

So what she's going to do is come in and talk to us a little bit about a topic that's near and dear to her heart, something that I believe you had done on Grand Rounds presentation. Yeah, that's right.

Thanks for having me here.

So what is the title of today's presentation?

So today's presentation is the new move, treating tardive dyskinesia.

So this is actually really interesting because I don't see a lot of tardive dyskinesia,

but I remember a lot about it from pharmacy school when we

learned about neuroleptics. So it sounds like there's some new movement in this area in terms

of new drugs. Yeah, that's right. Just last year we got FDA approval for two medications, Valbenazine

and Dutetrabenazine for tardive dyskinesia. And we'll be talking about those today. Right. So I guess just to lead off, Dr. Furbys, so can you tell for the audience that maybe less

submitted with those medications?

So what exactly is tardive dyskinesia?

Sure.

...